early recurrence of the primary tumor. The overall longterm survival rate is only 20-40%.
A number of approaches have been tried to improve the Between January 1993 and December 1996, 21 children with advanced solid tumors were entered in a dose-escaresult of HDCT. These approaches included increasing the number of agents in the myeloablative regimen and 'double lating study of high-dose sequential chemotherapy followed by autologous stem cell transplantation. The diaggrafting' -utilizing a second course of HDCT with an HSC infusion. Although preliminary data suggested improvenoses included neuroblastoma (NB) for 13 patients; Ewing's sarcoma (ES) for six patients and osteosarcoma ments in tumor response, significant obstacles were encountered. Extramedullary toxicities limit the dosage of each for two patients. Nine patients received therapy as consolidation for primary metastatic disease, and 12 drug in a multi-agent myeloablative regimen, 3 while cumulative toxicities and incomplete hematologic recovery patients had had previous relapses. Treatment consisted of CY given i.v. at a dose of 7 g/m 2 on day 1, followed between courses lead to a delay in treatment in a doublegrafting regimen. 4, 5 Delaying treatment may result in tumor by G-CSF until myeloid recovery. After 3 weeks of rest, all patients were given thiotepa i.v. on days 22-24. The progression in high-risk patients and good responders may elect not to receive a second course of HDCT. An increase total dose of thiotepa was 450 mg/m 2 in three patients, 600 mg/m 2 in six patients, and 750 mg/m 2 in 12 patients. in treatment-related mortality has also been reported. 5, 6 With these factors in mind, we developed a HDCT protoMelphalan was given i.v. at a dose of 180 mg/m 2 i.v. on day 27 followed by stem cell infusion on day 28. Major col designed to deliver maximum or near-maximum tolerated doses in rapid sequence. The first course consisted of toxic reactions included stomatitis, esophagitis, diarrhea and dermatitis. Three patients died of treatment-related high-dose CY, which regularly produces severe myelosuppression followed by a predictable recovery within complications. Twelve patients have had a relapse. Six patients (five with NB and one with ES) are alive in 3 weeks; this was followed by a second course of bialkylator HDCT and autologous HSC infusion. We report the continuous remission 5-50 months (median 36) after transplantation. The results of this study show that it is results of a phase I-II dose-escalation study utilizing this approach. feasible to administer high-dose sequential chemotherapy to children with advanced solid tumors. Keywords: sequential chemotherapy; autologous stem cell reinfusion; neuroblastoma; thiotepa; high-dose cyclophosphamide; melphalan
Patients and methods
The prognosis for children with disseminated or recurrent Patients solid tumors is poor. Few can be cured with conventional therapy, although many do show an initial, transient Twenty-one children with a relapsed or primary dissemiresponse to chemotherapy. It is postulated that dose intensinated solid tumor were entered in this study. Eligibility fication of cytotoxic agents followed by autologous hematorequirements included an age of 1-21 years, left ventricular poietic stem cell (HSC) infusion may improve disease-free ejection fraction Ͼ50%, serum creatinine and bilirubin levsurvival in these patients. The response rate of patients with els equal to or less than twice the upper limit of normal, advanced neuroblastoma (NB), Ewing's sarcoma (ES), or serum alkaline phosphatase and alanine aminotransferase rhabdomyosarcoma to a single course of high-dose chemolevels equal to or less than three times the upper limit of therapy (HDCT) has been encouraging. However, most normal, no history of macroscopic hematuria related to CY patients have had only a brief response, ending with an and Lansky's performance status Ͼ70%. Patients received treatment at least 4 weeks after undergoing myelosuppressive chemotherapy. The protocol was approved by the Insti-
Treatment plan
All patients underwent placement of multi-lumen indwelling central venous catheters and were cared for in Table 1 illustrates the treatment regimen, which consisted single hospital rooms. After the CY course, patients were of two courses. The first course consisted of CY alone. HSC discharged and prescribed a regimen of ciprofloxacin rescue was not given unless a surplus of cells was available.
20 mg/kg once daily by mouth as infection prophylaxis. After a minimum rest period of 3 weeks and after the They also took co-trimoxazole twice weekly by mouth and patient had recovered from the side-effects of this course rinsed with nystatin mouthwash. G-CSF was given s.c. at (ie resolution of all infections and an adequate performance a dose of 5 g/kg/day from day 1 until myeloid recovery. status but not dependent on blood counts), the second All patients were examined daily in the ambulatory clinic course of HDCT was administered. This course consisted until recovery of blood count. All patients received broadof thiotepa and melphalan. Autologous HSC infusions were spectrum antibiotics for neutropenic fever and irradiated, given 24 h after the administration of melphalan.
filtered blood products per standard routine. After receiving The total dose of CY was 7 g/m 2 . It was divided into four thiotepa and melphalan patients remained hospitalized for equal portions of 1.75 g/m 2 , each infused over 1 h. With a symptomatic care and hyperalimentation was started as 1-h rest period between each infusion, the whole CY regineeded. Administration of G-CSF at a dose of 5 g/kg was men lasted 7 h. Fluids were given i.v. at a dose of restarted the day after the HSC infusion. 150 ml/m 2 /h for at least 4 h prior to the first CY infusion and continued for a total of 48 h from the beginning of chemotherapy. Mesna was given i.v. at a dose of 10 mg/kg Toxicity grading and chemotherapy dose escalation every 4 h from 30 min prior to the first CY infusion to 48 h Early regimen-related toxicity (RRT) was graded according after the start of chemotherapy. Furosemide was given i.v.
to the criteria of Bearman et al. 7 In this system, grade I at a dose of 0.5 mg/kg 4 and 8 h from the first infusion of toxicity is reversible without treatment, grade II toxicity is CY. Thiotepa was given i.v. once daily as a 4-h infusion not life threatening but requires treatment, grade III toxicity for 3 consecutive days. To remove drug excreted in sweat, requires life support intervention, and grade IV toxicity is patients were required to shower thoroughly twice daily fatal. RRT in each organ system was scored as the highest (four times daily for the last eight patients) on the days grade achieved in that organ system to day 28 after HSC thiotepa was given and for 24 h after receiving the last dose infusion, except that deaths after day 28 that resulted from of thiotepa. Melphalan was given i.v. as a 4-h infusion.
RRT occurring before day 28 were also scored as grade IV. Adverse events that could be attributed to infection Supportive care (culture-documented), bleeding, or other medications were not scored. Bone marrow was harvested before the start of HDCT, at
The doses of CY and melphalan were kept the same least 3 weeks after any previous cytotoxic or radiation therthroughout the study. Patients were enrolled in groups of apy was completed. Harvest from patients with prior bone three for each thiotepa dose level. If none of the three marrow involvement was done after a microscopically patients in a group experienced grade III or IV toxicity, the 'negative' marrow examination was achieved. A minimum dose of thiotepa was increased. If one of the three patients of 1 × 10 8 total nucleated cells/kg was removed. Later in developed grade III or IV toxicity, an additional three the study, PBSC harvest was performed for all patients, if patients were accrued at that dose level. The maximum technically feasible. G-CSF was given at a dose of 5 g/kg thiotepa dose was reached if three or more patients in a s.c. every 12 h for 3 days, and leukapheresis was performed group of six developed grade III or IV toxicity. The dose on the fourth day until a minimum of 4 × 10 6 CD34 + of chemotherapy for patients aged 36 months and younger cells/kg were obtained. HSC were processed, frozen, was calculated on the basis of body weight (1 m 2 = 30 kg). thawed, and washed according to the standard technique.
Based on previous reports that determined the maximum If more than twice the targeted number of PBSC were coldose of thiotepa in combination with another agent for lected, half of the cells were reinfused after CY therapy.
HDCT, it was decided not to escalate the dose of thiotepa Purging or positive selection of HSC was not performed.
beyond level 3 (total dose = 750 mg/m 2 ). osseous sites and is only descriptively reported.
Results esophagitis, and watery diarrhea (Table 3) . Four patients required parenteral narcotics for pain relief. Desquamative dermatitis (grade II) affecting skin-fold areas was avoided Patients with increased frequency of showers after thiotepa adminisTwenty-one patients aged 1-17 (median 5.5 years) were tration. The resolution of these complications coincided enrolled in the study (Table 2 ). All patients had received a with neutrophil recovery. Two patients had congestive carmedian of two previous chemotherapy regimens (range 1-diac failure 2 and 5 weeks after HSC reinfusion, respect-4) and were exposed to a median of five (range 4-6) differively. Both had a documented concurrent infection, and carent cytotoxic agents. Nine patients received treatment durdiac function as measured by echocardiography reverted to ing the initial therapy; 12 patients had relapsed disease, six normal after appropriate treatment. of whom had progressive disease while receiving treatment.
None of the three patients treated at level 1 developed RRT higher than grade III, and the dose of thiotepa was escalated. At level 2, one of six patients had grade IV (fatal) Toxicities hepatic veno-occlusive disease (VOD) 2 weeks after HSC No patients developed grade 3 or 4 non-hematologic toxreinfusion. At level 3, two of 12 patients died of pulmonary icity after high-dose CY therapy. No cardiac abnormalities complications. One patient died on day 16 of a pulmonary or microscopic hematuria were detected. The most common hemorrhage after septicemic shock. Another patient died of side-effects encountered were nausea and vomiting, but adult respiratory distress syndrome on day 41 after an epithese were easily controlled with antiemetics. All patients sode of fungal pneumonia. but one were discharged 48 h after the start of CY therapy. Transient, direct hyperbilirubinemia (1.6-4.5 mg%) withHematopoietic recovery out concomitant liver enzyme abnormalities was encountered in five patients. All patients developed severe panAfter administration of high-dose CY, the median time to cytopenia, requiring red cell and platelet transfusions. Ten an ANC Ͼ0.5 × 10 9 /l was 12 days (range 10-18 days). Five patients were hospitalized for fever during the neutropenic patients received a portion of their PBSC after CY therapy phase, four of whom had documented bacteremia. All and their neutrophil and platelet recovery times were simipatients recovered from the side-effects of CY, and the lar to those of the rest of the patients (data not shown). The median time to the beginning of course 2 was 21 days median ANC and platelet count prior to the start of course (21-27 days).
2 was 1.8 × 10 9 (range 0.8-6.8) and 108 × 10 9 (range 29-All patients developed fever after the thiotepa-melphalan 458), respectively. course, eight of whom had documented bacteremia. There Nine patients received an autologous BMT and 12 were seven episodes of viral infection (herpes stomatitis, received PBSC reinfusion after thiotepa-melphalan therapy. three; herpes zoster, three; CMV viruria with hemorrhagic
The median number of nucleated cells infused was cystitis, one) that presented within 1 month of HSC re-5.9 × 10 8 /kg (range 1.2-18.9) actual body weight. One infusion. An episode of interstitial pneumonitis with negapatient died before hematopoietic recovery. An ANC tive bronchoalveolar lavage findings was also encountered.
Ͼ0.5 × 10 9 /l occurred at a median of 11 days (range 9-26 The patient responded to a course of erythromycin. days) after HSC infusion for the rest of the patients. The The predominant non-hematologic toxicity of course 2 last day of platelet transfusion occurred at a median of was to the gastrointestinal tract; manifested as stomatitis, 13 days (range 7-28 days) after HSC infusion. Five patients never attained platelet engraftment because of early death (three) or disease progression (two). No late graft failures Two patients died early after thiotepa-melphalan therapy CR1/VGPR1 4 PR1 2 and did not undergo disease re-evaluation for response. PR2 4 Five patients had no active disease prior to course 2 and RD 3 could not be assessed for response. At the initial re-evaluEwing's sarcoma (n = 6) ation of disease, five patients had a partial response, seven infusion. All survivors remained chemotherapy-sensitive at the time of HD therapy (CR1, one; PR1, three; CR2, one; vious studies that utilized high doses of thiotepa and melphalan as single agents, [15] [16] [17] and in combination with other and PR2, one patient, respectively).
drugs (eg busulfan), 18 the most significant toxicities encountered were oral mucositis, diarrhea, and moist desquamation of the skin. These complications resolved with Discussion hematologic recovery and can be managed by vigorous supportive care. Gianni et al [8] [9] [10] reported the use of a sequential HDCT regimen (CY followed by methotrexate, etoposide, and mel-
The transplant-related mortality in this series was 14% (three of 21 patients), with all three deaths occurring after phalan plus total body irradiation with autografting of HSC) over a total time span of 72 days for Hodgkin's disease and thiotepa-melphalan therapy. Two patients died of infectionrelated complications. The third died of hepatic VOD. This multiple myeloma patients with poor prognosis. For these chemotherapy-sensitive malignancies, complete remission death may have been related to the drug combination or to irradiation involving the liver prior to HDCT. When used rates of 72 and 77%, respectively, and disease-free survivals of 49 and 38%, respectively, were reported. We as single agents in high dosages, melphalan and thiotepa may rarely be associated with significant hepatotoxicity, 15-17 adopted a similar approach to test the feasibility of delivering, at the shortest possible intervals, non-crossand hepatic VOD had been encountered sporadically in regimens with either of these agents combined with other resistant drugs at or near maximum tolerated doses to children with advanced solid tumors. We found that the use of drugs in high doses. 19 Significant abnormal liver function tests were not seen in this series. Considering that the high-dose CY therapy as the first part of rapid-sequence HDCT was well tolerated. No cardiotoxicity caused by CY majority of the patients had been heavily pre-treated, the RRT encountered is comparable with that in other reports was detected; this is in accordance with animal and human experience showing that CY at a dose of 7 g/m 2 can be of pediatric patients undergoing a single course of myeloablative therapy followed by autologous HSC transsafely given in 1 day if it is divided into four or five fractions. 11, 12 Macroscopic hematuria was not seen after CY plantation. 3, [20] [21] [22] Although the primary goal of this trial was to evaluate but was encountered in one patient after thiotepa-melphalan therapy. Delayed onset of hemorrhagic cystitis has been the feasibility of administering high-dose cytotoxic therapy to children in rapid sequence, therapeutic responses were reported to be associated with an infectious (in this case CMV) etiology. 13 With the administration of G-CSF and seen in patients with residual disease at the time of HDCT. Six of 21 patients remain free of disease at the time of prophylactic ciprofloxacin, the incidence of fever during the neutropenic phase was only 50%. A single course of highreporting. This includes two patients with recurrent NB and one with metastatic ES. We did not select patients on the dose CY does not seem to affect the tolerability of subsequent HDCT. All but one patient recovered within basis of tumor sensitivity at the time of transplantation. Our results are similar, but not superior to, the results of other 4 weeks of CY therapy to receive the next course of highdose therapy. This is in contrast with other double-transhigh-dose regimens (including those using total body irradiation) and HSC transplantation for childhood solid plant protocols in which the time intervals between treatment courses were 2 to 6 months. 4, 5 Although only half of tumors. [20] [21] [22] In view of the small number of evaluable patients, this result should be considered as preliminary. the patients achieved a platelet count exceeding 100 × 10 9 /l prior to the start of the second course of HDCT, hemato-
The antitumor effects of our regimen can be better evaluated with a larger group of pediatric patients, preferably as logic recovery was not impaired after HSC reinfusion.
In this study, the administration of thiotepa in escalating consolidation therapy for less advanced cases. doses was combined with melphalan as the myeloablative regimen for autologous HSC transplantation. Level 3 (750 mg/m 2 of thiotepa and 180 mg/m 2 of melphalan) can References be tolerated by most children with advanced solid tumors. We did not attempt to escalate the dose of thiotepa further
